A possible turning point in the hematopoietic stem cell gene therapy for primary immunodeficiency diseases? Lentiviral vectors could take the place of retroviral vectors

Expert Review of Clinical Immunology

Volumn 9, Issue 11, 2013, Pages 1015-1018

  Ariga, Tadashi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

hematopoietic stem cell gene therapy; lentiviral vector; retroviral vector; vector integration sites; Wiskott Aldrich syndrome

Indexed keywords

BUSULFAN; FLUDARABINE; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ARTICLE; CLINICAL EFFECTIVENESS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE DEFICIENCY; INTERMETHOD COMPARISON; RISK ASSESSMENT; STEM CELL GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WISKOTT ALDRICH SYNDROME;

GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 84887302439     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.850416     Document Type: Article

References (17)

1. Massaad MJ, Ramesh N, Geha RF. Wiskott-Aldrich syndrome: a comprehensive review. Ann. N.Y. Acad. Sci. 1285, 26-43 (2013).
2. Ariga T. Wiskott-Aldrich syndrome; an x-linked primary immunodeficiency disease with unique and characteristic features. Allergol. Int. 61(2), 183-189 (2012).
3. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 78, 635-644 (1994).
4. Ochs HD, Notarangelo LD. Structure and function of the Wiskott-Aldrich syndrome protein. Curr. Opin. Hematol. 12(4), 284-291 (2005).
5. Ariga T, Oda N, Yamaguchi K et al. T cell lines from two patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation. Blood 97, 2896-2899 (2001).
6. Ariga T, Kondoh T, Yamaguchi K et al. Spontaneous in vivo reversion of an inherited mutation in the Wiskott-Aldrich syndrome. J. Immunol. 166, 5245-5249 (2001).
7. Seymour LW, Thrasher AJ. Gene therapy matures in the clinic. Nat. Biotechnol. 30(7), 588-593 (2012).
8. Boztug, K, Schmidt M, Schwarzer A et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 360(20), 1918-1927 (2010).
9. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S et al. Gene therapy for primary immunodeficiencies: part 1. Curr. Opin. Immunol. 24, 580-584 (2012).
10. Hacein-Bey-Abina S, Garrigue A, Wang GP et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142 (2008).
11. Stein S, Ott MG, Schultze-Strasser S et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16, 198-204 (2010).
12. Aiuti A, Bacchetta R, Seger R et al. Gene therapy for primary immunodeficiencies: Part 2. Curr. Opin. Immunol. 24, 585-591(2012).
13. Scaramuzza S, Biasco L, Ripamonti A et al. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol. Ther. 21, 175-184 (2013).
14. Cartier N, Hacein-Bey-Abina S, Bartholomae CC et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823 (2009).
15. Cavazzana-Calvo M, Payen E, Negre O et al. Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature 467, 318-322 (2010).
16. Aiuti A, Biasco L, Scaramuzza S et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341(6148), 1233151 (2013).
17. Biffi A, Montini E, Lorioli L et al. Therapeutic benefit in metachromatic leukodystrophy by lentiviral hematopoietic stem cell gene therapy. Science 341(6148), 1233158 (2013).